NSCLC, specifically, is driven by, usually mutually exclusive, mutations in RTKs, such as EGFR (1–15%, in non-Asian populations), HER2 (2–4%), ALK (3–7%), ROS1 (1–4%), KRAS (25%), and BRAF (3–5%) (Figure 1) [6,9,18,21,22,23]. Here, KRAS is linked to non-small cell lung carcinoma.